



US 20210317195A1

(19) **United States**(12) **Patent Application Publication** (10) **Pub. No.: US 2021/0317195 A1**  
(43) **Pub. Date: Oct. 14, 2021**  

---

(54) **POLYPEPTIDES****Publication Classification**(71) Applicant: **VHsquared Ltd.**, Cambridge (GB)(51) **Int. Cl.****C07K 16/12** (2006.01)**C07K 16/24** (2006.01)**C07K 16/28** (2006.01)(72) Inventors: **Scott Crowe**, Cambridge (GB); **Mike West**, Cambridge (GB); **Kevin Roberts**, Cambridge (GB); **Tim Carlton**, Cambridge (GB)(52) **U.S. Cl.**CPC ..... **C07K 16/1282** (2013.01); **C07K 16/241** (2013.01); **C07K 16/2866** (2013.01); **A61K 2039/542** (2013.01); **C07K 2317/94** (2013.01); **C07K 2317/22** (2013.01); **C07K 2317/565** (2013.01)(21) Appl. No.: **16/950,758**(22) Filed: **Nov. 17, 2020****Related U.S. Application Data**

(63) Continuation of application No. 15/717,230, filed on Sep. 27, 2017, now abandoned, which is a continuation of application No. PCT/EP2016/057024, filed on Mar. 31, 2016.

(30) **Foreign Application Priority Data**Mar. 31, 2015 (EP) ..... 15162115.8  
Jan. 21, 2016 (EP) ..... 16152320.4

(57)

**ABSTRACT**

There is provided inter alia a polypeptide comprising an immunoglobulin chain variable domain comprising three complementarity determining regions (CDR1-CDR3) and four framework regions, wherein: (a) at least one lysine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue, and/or (b) at least one arginine residue in CDR1, CDR2 and/or CDR3 has been substituted with at least one histidine residue; wherein the polypeptide has increased intestinal stability relative to a corresponding polypeptide not having said histidine substitutions.

**Specification includes a Sequence Listing.**